This company listing is no longer active
ABC Stock Overview
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Abcam plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£12.26 |
| 52 Week High | UK£17.60 |
| 52 Week Low | UK£10.14 |
| Beta | 0.46 |
| 1 Month Change | -14.09% |
| 3 Month Change | -14.21% |
| 1 Year Change | -25.70% |
| 3 Year Change | -12.74% |
| 5 Year Change | 20.20% |
| Change since IPO | 2,942.18% |
Recent News & Updates
Recent updates
Abcam plc (LON:ABC) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jun 24
Is Abcam (LON:ABC) A Risky Investment?
May 01Is There An Opportunity With Abcam plc's (LON:ABC) 39% Undervaluation?
Mar 08Calculating The Fair Value Of Abcam plc (LON:ABC)
Nov 22Shareholders Will Probably Be Cautious Of Increasing Abcam plc's (LON:ABC) CEO Compensation At The Moment
Jun 25Here's What We Think About Abcam's (LON:ABC) CEO Pay
Feb 09Abcam plc's (LON:ABC) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Jan 17Shareholders Are Thrilled That The Abcam (LON:ABC) Share Price Increased 124%
Dec 27Are Abcam's (LON:ABC) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 06
Shareholder Returns
| ABC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.1% | 0.5% | 2.7% |
| 1Y | -25.7% | -29.8% | 0.3% |
Return vs Industry: ABC exceeded the UK Biotechs industry which returned -33.5% over the past year.
Return vs Market: ABC underperformed the UK Market which returned -7% over the past year.
Price Volatility
| ABC volatility | |
|---|---|
| ABC Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ABC has not had significant price volatility in the past 3 months.
Volatility Over Time: ABC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,682 | Alan Hirzel | www.abcam.com |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.
Abcam plc Fundamentals Summary
| ABC fundamental statistics | |
|---|---|
| Market cap | UK£2.81b |
| Earnings (TTM) | UK£7.30m |
| Revenue (TTM) | UK£350.40m |
384.5x
P/E Ratio8.0x
P/S RatioIs ABC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABC income statement (TTM) | |
|---|---|
| Revenue | UK£350.40m |
| Cost of Revenue | UK£89.90m |
| Gross Profit | UK£260.50m |
| Other Expenses | UK£253.20m |
| Earnings | UK£7.30m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 74.34% |
| Net Profit Margin | 2.08% |
| Debt/Equity Ratio | 16.4% |
How did ABC perform over the long term?
See historical performance and comparison